Comparison of two neoadjuvant chemotherapy in locally advanced breast cancer patients; Adriamycin and Docetaxel (AD) versus Adriamycin, Cyclophosphamide followed by Paclitaxel (AC-T)

BACKGROUND: Neoadjuvant chemotherapy (NAC) is one of the standard treatmentfor the patients with locally advanced breast cancer and is an option for the patients with operable breast cancer. Such as adjuvant chemotherapy in breast cancer, anthracycline and taxane-based regimens have been studied and investigated as neoadjuvant setting. But, no one regimen has been shown to be superior in efficacy and toxicity view. MATERIALS AND METHODS: We compared the women received adriamycin and docetaxel (AD) with adriamycin, cyclophosphamide followed by paclitaxel (AC-T) as neoadjuvant chemotherapy from 1 November 2005 to 31 September2011. The AD group was scheduled for 6 cycles of AD (50mg/m2 and 75mg/m2, respectively) in the interval of 3 weeks. The AC-T group was scheduled for 4 cycles of AC regimen (60mg/m2 and 600mg/m2, respectively) followed by 4 cycles of paclitaxel (175mg/m2) in the interval of 3 weeks. All patients received complete resection for local control within 5 weeks after neoadjuvant chemotherapy. RESULTS: The patients enrolled in this study were totally 75 (AD 37 and AC-T 38). Among the patients’ baseline characteristics, clinical T stage was different between two groups. More advanced cases were included in AD group. The responses of chemotherapy were equivalent, which were estimated by overall response rate (AD 89% versus AC-T 87%,p=1.000), pathologic complete response (pCR) rate (breast and axilla; AD 11% versusAC-T 8%, p=0.711, breast only ;AD 19% versus AC-T 11%, p=0.346), breast conserving surgery rate (AD 62% versus AC-T 76%,p=0.184) and breast conserving surgery conversion rate (AD 24% versus AC-T 29%,p=0.651). Although non-hematologic toxicities were comparable, hematologic toxicities were more severe in AD group. Most women in AD group suffered from grade 3/4 neutropenia (p<0.001) and neutropenic fever (p<0.001). Also, Gankyrin expressions were not different between two groups except HER-2 positivity(p=0.028). CONCLUSIONS: AC-T regimen was moretolerable with similar clinical outcome than AD regimen in patients with breast cancer receiving NAC.

Author dc:creator

• 전, 자영

Contributors dc:contributor

• 강, 석윤
• 대학원 의학과
• 106806

• 유방암
• 선행항암화학적요법
• 종양 반응
• 병리학적 완전관해율
• Gankyrin

Language dc:language

ko

Identifier

http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000013391
000000013391

OAI identifier oai:identifier

oai:repository.ajou.ac.kr:201003/8623